Bioventus Inc. revised earnings guidance for the full-year 2024. Based on strong execution and significant momentum across the business, Bioventus is raising financial guidance for full-year 2024. The Company now expects Net sales of $535 million to $550million, an increase of $15 million from previous guidance.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
6.705 USD | +5.26% | +10.23% | +28.84% |
May. 07 | Bioventus Inc. Revises Earnings Guidance for the Full-Year 2024 | CI |
May. 07 | Transcript : Bioventus Inc., Q1 2024 Earnings Call, May 07, 2024 |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+28.84% | 407M | |
+75.57% | 12.55B | |
-23.67% | 7.51B | |
+8.49% | 6.74B | |
+14.95% | 5.48B | |
-14.65% | 4.93B | |
+30.59% | 4.71B | |
-24.40% | 3.83B | |
-23.20% | 2.9B | |
+49.16% | 2.49B |
- Stock Market
- Equities
- BVS Stock
- News Bioventus Inc.
- Bioventus Inc. Revises Earnings Guidance for the Full-Year 2024